#China #Suzhou #siRNA #Ribo #RiboPepSTAR

Ribo Life Science Unveils RiboPepSTAR™ for Enhanced siRNA Delivery

In a significant stride towards revolutionizing RNA therapeutics, Suzhou Ribo Life Science Co., Ltd. has introduced their latest innovation, RiboPepSTAR™. This proprietary technology enables targeted siRNA delivery to various organs, stepping beyond the liver, where traditional siRNA therapies have often been limited. Ribo, which is publicly traded on the Hong Kong Stock Exchange under the code 6938, recently showcased RiboPepSTAR™ at the RNA Leaders Europe Conference in Vienna, Austria.

Building on Past Success with RiboGalSTAR™

RiboPepSTAR™ is a natural progression following the success of its predecessor, RiboGalSTAR™, which has successfully supported seven clinical programs, leading to significant global partnerships valued at over USD 6 billion. The new technology is geared towards addressing the limitations of prior siRNA delivery systems, with promising preclinical data demonstrating effective delivery across multiple tissues.

Expanding Target Areas: The Kidney, Heart, and Beyond

RiboPepSTAR™ has shown particular promise in targeting the kidney, heart, and adipose tissue, providing hope for treating chronic diseases prevalent in these areas. In recent preclinical studies, the technology enabled select uptake in proximal tubular cells within the kidney, achieving an impressive 80% target gene knockdown over various models, including rodent and non-human primate (NHP) studies.

Key findings included robust kidney-specific reductions in biomarkers associated with diseases like Type 2 Diabetes, as well as advancements toward an Investigational New Drug (IND) submission for Ribo's first kidney-targeted drug.

In cardiac studies, the RiboPepSTAR™ produced substantial gene knockdown specifically in heart tissue, with minimal effects seen in other muscles or organs, confirming its specificity for cardiac applications. Such selectivity is crucial for developing targeted therapies that minimize off-target effects and enhance patient safety.

Moreover, in adipose health research utilizing NHP subjects, a remarkable 96% knockdown was achieved, emphasizing RiboPepSTAR™'s potential in addressing metabolic diseases through targeted delivery to adipose tissue.

Multi-target siRNA Platform: A New Frontier

Accompanying the advancements in delivery mechanisms, Ribo is also progressing its multi-target siRNA platform. This groundbreaking method allows a single molecule to silence multiple genes simultaneously. The dual-target siRNAs developed by Ribo demonstrate knockdown efficacy comparable to that of traditional single-target approaches, facilitating enhanced therapeutic benefits. This capability to modulate multiple pathways amplifies the potential impact of their siRNA therapies, broadening the scope of diseases that can be effectively treated.

Commitment to Future Therapies

Ribo Life Science's continuous innovations in siRNA technology reflect their commitment to bringing next-generation medicines to a global patient population. The advancements presented through RiboPepSTAR™ offer promising avenues for treating renal, cardiac, and metabolic diseases, aligning with Ribo's mission of delivering cutting-edge medical therapies.

These developments not only signify a leap in treating complex diseases but also highlight Ribo Life Science’s steadfast dedication to advancing RNA technology for improved health outcomes worldwide. As they pave the way for new therapeutic possibilities, healthcare professionals and patients alike look forward to the impact of their findings in clinical settings.